CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

NCT01199068 ↗

Phase 1 Completed 15 enrolled Daiichi Sankyo ICON Clinical Research · collab

NaSingle-groupOpen-labelTreatment

Summary

The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with erlotinib, and to assess the pharmacokinetics of CS-7017 in combination with erlotinib.

Timeline

Start: 2010-06
Primary completion: 2011-12
Completion: 2011-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	efatutazone	Small molecule	0.25 mg	Oral
Subject	efatutazone	Small molecule	0.5 mg	Oral
Background	Erlotinib	Small molecule	150 mg	—

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Summary

Timeline

Drugs

Indications